![Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology](https://www.futuremedicine.com/cms/10.2217/fmb.11.84/asset/images/medium/figure2.gif)
Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology
![Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology](https://www.futuremedicine.com/cms/10.2217/fmb.11.84/asset/images/medium/figure3.gif)
Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology
![Predictable repeatability issues with GeneXpert-Xpert MTB/RIF (version 4) derived rifampicin resistant tuberculosis results from South India: Appreciating the limits of a technological marvel! Sanker P, Kottuthodi RP, Ambika AP, Santhosh VT, Balakrishnan Predictable repeatability issues with GeneXpert-Xpert MTB/RIF (version 4) derived rifampicin resistant tuberculosis results from South India: Appreciating the limits of a technological marvel! Sanker P, Kottuthodi RP, Ambika AP, Santhosh VT, Balakrishnan](https://www.bmbtrj.org/articles/2017/1/1/images/BiomedBiotechnolResJ_2017_1_1_76_211417_f2.jpg)
Predictable repeatability issues with GeneXpert-Xpert MTB/RIF (version 4) derived rifampicin resistant tuberculosis results from South India: Appreciating the limits of a technological marvel! Sanker P, Kottuthodi RP, Ambika AP, Santhosh VT, Balakrishnan
![Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology](https://www.futuremedicine.com/cms/10.2217/fmb.11.84/asset/images/medium/figure1.gif)
Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance | Future Microbiology
![Discordant results of Xpert MTB/Rif assay and BACTEC MGIT 960 liquid culture to detect Mycobacterium tuberculosis in community screening in Vietnam | springermedizin.de Discordant results of Xpert MTB/Rif assay and BACTEC MGIT 960 liquid culture to detect Mycobacterium tuberculosis in community screening in Vietnam | springermedizin.de](https://media.springernature.com/lw367/springer-static/image/art%3A10.1186%2Fs12879-022-07481-5/MediaObjects/12879_2022_7481_Fig2_HTML.png?as=jpg)
Discordant results of Xpert MTB/Rif assay and BACTEC MGIT 960 liquid culture to detect Mycobacterium tuberculosis in community screening in Vietnam | springermedizin.de
![Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. | Semantic Scholar Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e0b0f4b3464fa656ea7d3be3d7ef1993554cac53/5-Table1-1.png)
Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda. | Semantic Scholar
![Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test - The Lancet Infectious Diseases Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/9763eeab-5e83-4cfa-860f-6eac8102481c/gr1_lrg.jpg)
Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test - The Lancet Infectious Diseases
![Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda - The Lancet Microbe Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda - The Lancet Microbe](https://www.thelancet.com/cms/attachment/b4cf3d53-b095-482e-8a78-7922af514977/gr1.gif)
Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda - The Lancet Microbe
![Diagnostic performance and impact of routinely implemented Xpert® MTB/RIF assay in a setting of high incidence of drug-resistant TB in Odessa Oblast, Ukraine - ScienceDirect Diagnostic performance and impact of routinely implemented Xpert® MTB/RIF assay in a setting of high incidence of drug-resistant TB in Odessa Oblast, Ukraine - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1198743X18308012-gr1.jpg)
Diagnostic performance and impact of routinely implemented Xpert® MTB/RIF assay in a setting of high incidence of drug-resistant TB in Odessa Oblast, Ukraine - ScienceDirect
Identification of Mycobacterium tuberculosis from pericardial fluid using the new Xpert MTB/RIF assay
![4.1.1 Decision pathway for Algorithm 1 – mWRD as the initial diagnostic test for TB | TB Knowledge Sharing 4.1.1 Decision pathway for Algorithm 1 – mWRD as the initial diagnostic test for TB | TB Knowledge Sharing](https://tbksp.org/sites/default/files/inline-images/1C-Molecular-WRD-as-the-initial-diagnostic-test-for-TB.gif)
4.1.1 Decision pathway for Algorithm 1 – mWRD as the initial diagnostic test for TB | TB Knowledge Sharing
![PDF) Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: A retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settings PDF) Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: A retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settings](https://i1.rgstatic.net/publication/311753037_Performance_of_the_G4_XpertR_MTBRIF_assay_for_the_detection_of_Mycobacterium_tuberculosis_and_rifampin_resistance_A_retrospective_case-control_study_of_analytical_and_clinical_samples_from_high-_and_l/links/5859477d08ae3852d2559153/largepreview.png)
PDF) Performance of the G4 Xpert® MTB/RIF assay for the detection of Mycobacterium tuberculosis and rifampin resistance: A retrospective case-control study of analytical and clinical samples from high- and low-tuberculosis prevalence settings
![Ungoofaaru Regional Hospital on Twitter: "MTB Test run in GeneXpert Machine today. The GeneXpert MTB/RIF result is quicker & helps in selecting treatment regimens and reaching #TB control decisions quickly Thanks to @ Ungoofaaru Regional Hospital on Twitter: "MTB Test run in GeneXpert Machine today. The GeneXpert MTB/RIF result is quicker & helps in selecting treatment regimens and reaching #TB control decisions quickly Thanks to @](https://pbs.twimg.com/media/EegVCwlU4AAbFMS.jpg)
Ungoofaaru Regional Hospital on Twitter: "MTB Test run in GeneXpert Machine today. The GeneXpert MTB/RIF result is quicker & helps in selecting treatment regimens and reaching #TB control decisions quickly Thanks to @
![A Comparative Evaluation of the New Genexpert MTB/RIF Ultra and other Rapid Diagnostic Assays for Detecting Tuberculosis in Pulmonary and Extra Pulmonary Specimens | Scientific Reports A Comparative Evaluation of the New Genexpert MTB/RIF Ultra and other Rapid Diagnostic Assays for Detecting Tuberculosis in Pulmonary and Extra Pulmonary Specimens | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-019-53086-5/MediaObjects/41598_2019_53086_Fig1_HTML.png)